Acute ischemic stroke (AIS) occurs when blood flow through a brain artery is obstructed by a clot, which is a thickened mass of blood. Clots are classified as either thrombotic or embolic depending on where they form in the body. The most common type of stroke is a thrombotic stroke, which occurs when a clot forms within a brain artery. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from another part of the body, such as the heart, and travels through the bloodstream before becoming lodged in a narrower vessel in the brain. Large vessel occlusion (LVO) is responsible for nearly half of all acute ischemic strokes. LVO is the most serious and debilitating type of stroke because the clot blocks large arteries and prevents blood flow to essential parts of the brain.
The global acute ischemic stroke (AIS) market is estimated to be valued at US$ 8,517.0 million in 2021 and is expected to increase to US$ 11,185.3 Mn by 2028, witnessing a CAGR of 4.0% over the forecast period (2021-2028).
Figure 1. Global Acute Ischemic Stroke (AIS) Market Value (US$ Mn) & Y-o-Y Growth (%)
-market-fig-1.png "Acute Ischemic Stroke Therapeutics | CMI")
Increasing prevalence of ischemic stroke globally is expected to drive the growth of the global acute ischemic stroke (AIS) market.
For instance, as per the 2021 Heart Disease & Stroke Statistical Update Fact Sheet provided by the American Heart Association, the global prevalence of stroke in 2019 was 101.5 million people, while that of ischemic stroke was 77.2 million. Overall, age-standardized stroke prevalence rate in 2019 was highest in Oceania, Southeast Asia, North Africa, and the Middle East, as well as East Asia. Countries in parts of North Africa and the Middle East, Southern sub-Saharan Africa, high-income countries in North America and Southeast Asia had the highest ischemic stroke prevalence rate. Furthermore, in 2019, there were 6.6 million deaths worldwide due to cerebrovascular diseases. In 2019, a total of 3.3 million people worldwide died from ischemic stroke, 2.9 million died from intracerebral hemorrhage, and 0.4 million died from subarachnoid hemorrhage.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 8,517.0 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 4.0% | 2028 Value Projection: | US$ 11,185.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Acute Ischemic Stroke (AIS) Market Share (%), By Region, 2021
-market-fig-2.png "Acute Ischemic Stroke Therapeutics | CMI")
Global Acute Ischemic Stroke (AIS) Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic.
In the context of the coronavirus (COVID-19) global pandemic caused by SARS-CoV-2, a possible link between this disease and stroke has been proposed. Between March 24, 2020 and July 17, 2020, PCR-confirmed COVID-19 patients with ischemic stroke were admitted to an academic health system in metropolitan Atlanta, Georgia (U.S.). 13 (2.5%) of 396 ischemic stroke patients admitted during this study period were also diagnosed with COVID-19. Each of the 13 patients had at least one stroke-related co-morbidity. The most common type of ischemic stroke was embolic, with four cases explained by atrial fibrillation. During the study period, COVID-19 patients had a significantly higher rate of cryptogenic stroke than non-COVID-19 patients.
Global Acute Ischemic Stroke (AIS) Market: Restraint
High cost of treatment and lack of transparent reimbursement policies is expected to restrain the market growth over the forecast period. For instance, according to an article published by National Center for Biotechnology Information (NCBI), published in August 2018, the average in-hospital cost per acute stroke patient was approximately US$ 6961 ± 15,663 in Lebanon. Cost determinants were length of hospital stay, length of intensive care unit stay, stroke type, stroke severity, modified Rankin scale, third-party payers, operations, and infectious complications.
Key Players
Major players operating in the global acute ischemic stroke (AIS) market include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc.
Acute ischemic stroke (AIS) is defined as the sudden loss of blood flow to an area of the brain with the consequent loss of neurological function. It is caused due to thrombotic or embolic occlusion of a cerebral artery and is more common than hemorrhagic stroke. Symptoms depend on the severity of the stroke and its location in the brain. Few people have no symptoms while Online Pharmacies only have one of the numerous symptoms. However, most people experience a combination of symptoms such as paralysis on one side of the body, changes in alertness, and changes in hearing or taste, difficulty in swallowing, dizziness or loss of balance, visual disturbances, and others.
Market Dynamics
Tobacco smoking is one of the major cause of cardiovascular disease, such as coronary heart disease, high blood pressure, heart attack, stroke, and Online Pharmacies. When a person smokes a cigarette, the blood that is distributed to the rest of the body becomes contaminated with chemicals in the smoke. These chemicals can damage the heart and blood vessels, which can lead to cardiovascular disease (CVD), the leading cause of death in the U.S. For instance, key facts provided by World Health Organization (WHO) in 2021, tobacco kills more than eight million people each year, globally. More than seven million of these deaths are due to direct tobacco use, while about 1.2 million are due to non-smokers exposed to secondhand smoke (combination of smoke from the burning end of a cigarette and the smoke breathed out by smokers). More than 80% of the world's 1.3 billion tobacco users live in low- and middle-income countries such as Bangladesh, India, Afghanistan, and Online Pharmacies.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients